Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03635892 · ClinicalTrials.gov registry record · Phase 2

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

A Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
60
Enrollment target
7
Study locations

NCT03635892 is a Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, below the 226-participant average among 8 other Chromophobe Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03635892, a Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.

Conditions Studied

Chromophobe Renal Cell Carcinoma Papillary Renal Cell Carcinoma Unclassified Renal Cell Carcinoma Succinate Dehydrogenase-Deficient Renal Cell Carcinoma Collecting Duct Renal Cell Carcinoma Fumarate Hydratase Deficient Renal Cell Carcinoma Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma

Interventions

  • DRUG nivolumab
  • DRUG cabozantinib

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-08-13
Est. Completion 2026-08
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03635892

The ClinicalTrials.gov registry entry for NCT03635892 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 8 other Chromophobe Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Chromophobe Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.

NCT03635892 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03635892 about?

NCT03635892 is a clinical study titled "A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma". The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.

What is the current status of trial NCT03635892?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-08-13. Estimated completion is 2026-08.

What conditions does trial NCT03635892 study?

This clinical trial studies the following conditions: Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma.

What interventions are being tested in trial NCT03635892?

The interventions under investigation include: nivolumab (DRUG), cabozantinib (DRUG).

Who is sponsoring clinical trial NCT03635892?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03635892 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chromophobe Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chromophobe Renal Cell Carcinoma

All registered trials for this condition

Papillary Renal Cell Carcinoma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.